The Society of Breast Imaging (SBI) is working with the American College of Radiology (ACR) to host its annual Breast Imaging Symposium April 12-15 in Las Vegas.

Jay A. Baker, MD, professor of radiology and chief of the breast imaging division at Duke University Medical Center in Durham, North Carolina, and the vice president of the Society of Breast Imaging (SBI), spoke with Radiology Business about some of the biggest topics affecting breast imaging today.

CHICAGO, Nov. 27, 2017 /PRNewswire/ -- Seno Medical Instruments, Inc. (Seno Medical), the leader in new technology for breast cancer diagnosis using opto-acoustic ultrasound (OA/US) imaging to differentiate benign from malignant masses, today announced positive data from PIONEER, a Phase III pivotal trial of its Imagio™ breast imaging system. The study found that OA/US was more specific than device gray-scale ultrasound alone (US) in differentiating malignant from benign breast lesions and was non-inferior to US with respect to sensitivity.

Shortly before her 40th birthday, a woman visits her primary care physician and is advised she should schedule her first mammogram. The patient is puzzled and says she “read somewhere” that she can wait a few years. The physician has heard this before and kindly convinces the patient to comply with the recommendation. She agrees, schedules the mammogram and receives her results before even leaving the imaging facility. 

Multiple patient advocacy groups and healthcare organizations, including the American College of Radiology (ACR) and Society of Breast Imaging (SBI), are asking Congress to extend a federal mandate that requires insurance companies to fully insure annual mammograms for women 40 years old and older. 

Architectural distortion, the non-mass but potentially ominous clinical feature observed in many breast imaging procedures, is less likely to signal malignancy when it’s detected on screening mammography rather than diagnostic mammography or when it does not correlate with a subsequent targeted ultrasound exam.

Seno Medical Instruments, Inc. (Seno), the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed the final phase of the company's U.S.-based PIONEER Pivotal Study of the Imagio® breast imaging system. 

FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging solutions, has submitted to the U.S. Food and Drug Administration (FDA) the first module of its premarket approval (PMA) application for digital breast tomosynthesis* (DBT), as an optional upgrade for the Aspire Cristalle mammography system.